{"id":679,"date":"2017-03-24T14:12:20","date_gmt":"2017-03-24T14:12:20","guid":{"rendered":"http:\/\/blog.valuengine.com\/?p=679"},"modified":"2017-03-24T15:01:01","modified_gmt":"2017-03-24T15:01:01","slug":"valuengine-weekly-medical-stocks-intel-valuation-watch-and-more","status":"publish","type":"post","link":"http:\/\/blog.valuengine.com\/index.php\/valuengine-weekly-medical-stocks-intel-valuation-watch-and-more\/","title":{"rendered":"ValuEngine Weekly: Medical Stocks, Intel, Valuation Watch, and More"},"content":{"rendered":"

This week, we provide top-five ranked VE data for our Medical stocks. We take a look at our latest data on Intel $INTC. We currently have an overvaluation watch underway.<\/strong><\/span><\/p>\n

VALUATION WATCH: Overvalued stocks now make up 64.57% of our stocks assigned a valuation and 31.59% of those equities are calculated to be overvalued by 20% or more. Fifteen sectors are calculated to be overvalued.<\/strong><\/span><\/p>\n

ValuEngine Index Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Index<\/td>\nWeek Open<\/td>\nFriday AM<\/td>\nChange<\/td>\n% Change<\/td>\nYTD<\/td>\n<\/tr>\n
DJIA<\/strong><\/td>\n20916.27<\/td>\n20694.72<\/td>\n-221.55<\/td>\n-1.06%<\/td>\n4.72%<\/td>\n<\/tr>\n
NASDAQ<\/strong><\/td>\n5898.81<\/td>\n5841.32<\/td>\n-57.49<\/td>\n-0.97%<\/td>\n8.51%<\/td>\n<\/tr>\n
RUSSELL 2000<\/strong><\/td>\n1391.46<\/td>\n1353.43<\/td>\n-38.03<\/td>\n-2.73%<\/td>\n-0.27%<\/td>\n<\/tr>\n
S&P 500<\/strong><\/td>\n2378.24<\/td>\n2351.45<\/td>\n-26.79<\/td>\n-1.13%<\/td>\n5.03%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Market Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Summary of VE Stock Universe<\/td>\n<\/tr>\n
Stocks Undervalued <\/strong><\/td>\n35.43%<\/td>\n<\/tr>\n
Stocks Overvalued <\/strong><\/td>\n64.57%<\/td>\n<\/tr>\n
Stocks Undervalued by 20% <\/strong><\/td>\n14.98%<\/td>\n<\/tr>\n
Stocks Overvalued by 20% <\/strong><\/td>\n26.13%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Sector Overview<\/strong><\/h1>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Sector<\/td>\nChange<\/td>\nMTD<\/td>\nYTD<\/td>\nValuation<\/td>\nLast 12-MReturn<\/td>\nP\/E Ratio<\/td>\n<\/tr>\n
Multi-Sector Conglomerates<\/a><\/td>\n0.57%<\/td>\n1.51%<\/td>\n6.23%<\/td>\n17.25% overvalued<\/td>\n14.12%<\/td>\n20.16<\/td>\n<\/tr>\n
Computer and Technology<\/a><\/td>\n0.29%<\/td>\n1.11%<\/td>\n7.85%<\/td>\n16.63% overvalued<\/td>\n23.30%<\/td>\n31.30<\/td>\n<\/tr>\n
Industrial Products<\/a><\/td>\n0.86%<\/td>\n-0.73%<\/td>\n2.16%<\/td>\n16.21% overvalued<\/td>\n22.49%<\/td>\n25.46<\/td>\n<\/tr>\n
Aerospace<\/a><\/td>\n0.39%<\/td>\n-2.39%<\/td>\n1.28%<\/td>\n13.52% overvalued<\/td>\n24.44%<\/td>\n19.97<\/td>\n<\/tr>\n
Utilities<\/a><\/td>\n-0.02%<\/td>\n1.09%<\/td>\n2.57%<\/td>\n12.29% overvalued<\/td>\n20.04%<\/td>\n23.08<\/td>\n<\/tr>\n
Finance<\/a><\/td>\n0.47%<\/td>\n-2.13%<\/td>\n1.79%<\/td>\n10.89% overvalued<\/td>\n17.76%<\/td>\n17.48<\/td>\n<\/tr>\n
Construction<\/a><\/td>\n0.39%<\/td>\n-0.49%<\/td>\n6.88%<\/td>\n10.20% overvalued<\/td>\n23.29%<\/td>\n21.34<\/td>\n<\/tr>\n
Business Services<\/a><\/td>\n0.35%<\/td>\n-0.87%<\/td>\n3.05%<\/td>\n10.20% overvalued<\/td>\n13.71%<\/td>\n24.66<\/td>\n<\/tr>\n
Consumer Staples<\/a><\/td>\n0.18%<\/td>\n0.65%<\/td>\n3.49%<\/td>\n10.18% overvalued<\/td>\n13.07%<\/td>\n25.08<\/td>\n<\/tr>\n
Transportation<\/a><\/td>\n0.24%<\/td>\n-3.04%<\/td>\n2.24%<\/td>\n7.16% overvalued<\/td>\n14.95%<\/td>\n19.16<\/td>\n<\/tr>\n
Auto-Tires-Trucks<\/a><\/td>\n0.51%<\/td>\n-0.71%<\/td>\n3.28%<\/td>\n6.83% overvalued<\/td>\n27.59%<\/td>\n14.33<\/td>\n<\/tr>\n
Consumer Discretionary<\/a><\/td>\n0.67%<\/td>\n0.95%<\/td>\n3.87%<\/td>\n6.41% overvalued<\/td>\n17.97%<\/td>\n25.56<\/td>\n<\/tr>\n
Basic Materials<\/a><\/td>\n0.07%<\/td>\n-2.20%<\/td>\n5.73%<\/td>\n4.90% overvalued<\/td>\n47.77%<\/td>\n26.81<\/td>\n<\/tr>\n
Medical<\/a><\/td>\n0.31%<\/td>\n-1.99%<\/td>\n7.99%<\/td>\n1.74% overvalued<\/td>\n13.99%<\/td>\n27.69<\/td>\n<\/tr>\n
Retail-Wholesale<\/a><\/td>\n0.51%<\/td>\n-1.15%<\/td>\n-1.01%<\/td>\n1.74% overvalued<\/td>\n4.12%<\/td>\n23.48<\/td>\n<\/tr>\n
Oils-Energy<\/a><\/td>\n0.34%<\/td>\n-4.74%<\/td>\n-4.58%<\/td>\n2.16% undervalued<\/td>\n17.67%<\/td>\n30.11<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Sector Talk–Medical<\/strong><\/h1>\n

Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service<\/a>. <\/strong>Top- five lists are provided for each category.\u00a0 We applied some basic liquidity criteria–share price greater than $3 and average daily volume in excess of 100k shares.<\/p>\n

Top-Five Medical Stocks–Short-Term Forecast Returns<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
EGRX<\/td>\nEAGLE PHARMACT<\/td>\n81.83<\/td>\n-6.51%<\/td>\n97.51%<\/td>\n<\/tr>\n
ANIP<\/td>\nANI PHARMACEUT<\/td>\n45.54<\/td>\n-13.30%<\/td>\n38.04%<\/td>\n<\/tr>\n
LNTH<\/td>\nLANTHEUS HLDGS<\/td>\n11.9<\/td>\nN\/A<\/td>\n513.40%<\/td>\n<\/tr>\n
LCI<\/td>\nLANNETT INC<\/td>\n21.2<\/td>\n-45.56%<\/td>\n4.13%<\/td>\n<\/tr>\n
SCMP<\/td>\nSUCAMPO PHARMAC<\/td>\n10.75<\/td>\n-30.84%<\/td>\n6.02%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Momentum<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
AKAO<\/td>\nACHOGEN INC<\/td>\n20.3<\/td>\n223.89%<\/td>\n574.42%<\/td>\n<\/tr>\n
LNTH<\/td>\nLANTHEUS HLDGS<\/td>\n11.9<\/td>\nN\/A<\/td>\n513.40%<\/td>\n<\/tr>\n
EXEL<\/td>\nEXELIXIS INC<\/td>\n20.31<\/td>\n79.04%<\/td>\n411.59%<\/td>\n<\/tr>\n
CRBP<\/td>\nCORBUS PHARMACT<\/td>\n9<\/td>\nN\/A<\/td>\n381.28%<\/td>\n<\/tr>\n
AERI<\/td>\nAERIE PHARMACT<\/td>\n45.6<\/td>\n127.91%<\/td>\n285.79%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Composite Score<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
EGRX<\/td>\nEAGLE PHARMACT<\/td>\n81.83<\/td>\n-6.51%<\/td>\n97.51%<\/td>\n<\/tr>\n
AZN<\/td>\nASTRAZENECA PLC<\/td>\n31.3<\/td>\n0.64%<\/td>\n11.75%<\/td>\n<\/tr>\n
HCA<\/td>\nHCA HOLDINGS<\/td>\n83.17<\/td>\n-10.34%<\/td>\n8.08%<\/td>\n<\/tr>\n
BIIB<\/td>\nBIOGEN INC<\/td>\n275.41<\/td>\n-17.61%<\/td>\n7.90%<\/td>\n<\/tr>\n
ANIP<\/td>\nANI PHARMACEUT<\/td>\n45.54<\/td>\n-13.30%<\/td>\n38.04%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Most Overvalued<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
ICPT<\/td>\nINTERCEPT PHARM<\/td>\n115.8<\/td>\n300.00%<\/td>\n-5.59%<\/td>\n<\/tr>\n
TSRO<\/td>\nTESARO INC<\/td>\n153.62<\/td>\n269.32%<\/td>\n233.59%<\/td>\n<\/tr>\n
AKAO<\/td>\nACHOGEN INC<\/td>\n20.3<\/td>\n223.89%<\/td>\n574.42%<\/td>\n<\/tr>\n
DEPO<\/td>\nDEPOMED INC<\/td>\n14.84<\/td>\n207.30%<\/td>\n12.94%<\/td>\n<\/tr>\n
CYH<\/td>\nCOMMNTY HLTH SY<\/td>\n8.7<\/td>\n195.72%<\/td>\n-51.04%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Free Download for Readers<\/strong><\/h1>\n

As a bonus to our Free Weekly Newsletter subscribers,
\nwe are offering a FREE DOWNLOAD of one of our Stock Reports<\/strong><\/em><\/p>\n

Intel Corporation (INTC) is one of the world’s largest semiconductor chip maker. The Company develops advanced integrated digital technology products, primarily integrated circuits, for industries such as computing and communications. It also develops platforms, which it defines as integrated suites of digital computing technologies that are designed and configured to work together to provide an optimized user computing solution compared to components that are used separately. Intel designs and manufactures computing and communications components, such as microprocessors, chipsets, motherboards, and wireless and wired connectivity products, as well as platforms that incorporate these components. The Company sells its products primarily to original equipment manufacturers, original design manufacturers, PC and network communications products users, and other manufacturers of industrial and communications equipment. Intel Corporation is based in Santa Clara, California.<\/p>\n

VALUENGINE RECOMMENDATION: ValuEngine continues its BUY recommendation on INTEL CORP for 2017-03-23. Based on the information we have gathered and our resulting research, we feel that INTEL CORP has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and P\/E Ratio.<\/p>\n

You can download a free copy of detailed report on Intel Corporation (INTC) from the link below.<\/p>\n

R<\/strong><\/em>ead our Complete Rating and Forecast Report on Intel (INTC) <\/strong><\/em>HERE.<\/strong><\/a><\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n
ValuEngine Forecast<\/strong><\/td>\n<\/tr>\n
<\/td>\nTarget
\nPrice*<\/th>\n		Expected
\nReturn<\/th>\n<\/tr>\n
1-Month<\/strong><\/td>\n35.46<\/td>\n0.54%<\/td>\n<\/tr>\n
3-Month<\/strong><\/td>\n35.82<\/td>\n1.56%<\/td>\n<\/tr>\n
6-Month<\/strong><\/td>\n35.87<\/td>\n1.71%<\/td>\n<\/tr>\n
1-Year<\/strong><\/td>\n37.55<\/td>\n6.46%<\/td>\n<\/tr>\n
2-Year<\/strong><\/td>\n38.95<\/td>\n10.44%<\/td>\n<\/tr>\n
3-Year<\/strong><\/td>\n39.15<\/td>\n11.00%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Valuation & Rankings<\/strong><\/td>\n<\/tr>\n
Valuation<\/strong><\/td>\n6.80% overvalued<\/td>\nValuation Rank<\/strong>(?<\/a>)<\/td>\n53<\/td>\n<\/tr>\n
1-M Forecast Return<\/strong><\/td>\n0.54%<\/td>\n1-M Forecast Return Rank<\/strong><\/td>\n86<\/td>\n<\/tr>\n
12-M Return<\/strong><\/td>\n10.22%<\/td>\nMomentum Rank<\/strong>(?<\/a>)<\/td>\n45<\/td>\n<\/tr>\n
Sharpe Ratio<\/strong><\/td>\n0.29<\/td>\nSharpe Ratio Rank<\/strong>(?<\/a>)<\/td>\n68<\/td>\n<\/tr>\n
5-Y Avg Annual Return<\/strong><\/td>\n5.95%<\/td>\n5-Y Avg Annual Rtn Rank<\/strong><\/td>\n64<\/td>\n<\/tr>\n
Volatility<\/strong><\/td>\n20.41%<\/td>\nVolatility Rank<\/strong>(?<\/a>)<\/td>\n70<\/td>\n<\/tr>\n
Expected EPS Growth<\/strong><\/td>\n-0.24%<\/td>\nEPS Growth Rank<\/strong>(?<\/a>)<\/td>\n21<\/td>\n<\/tr>\n
Market Cap (billions)<\/strong><\/td>\n170.53<\/td>\nSize Rank<\/strong><\/td>\n100<\/td>\n<\/tr>\n
Trailing P\/E Ratio<\/strong><\/td>\n12.63<\/td>\nTrailing P\/E Rank<\/strong>(?<\/a>)<\/td>\n86<\/td>\n<\/tr>\n
Forward P\/E Ratio<\/strong><\/td>\n12.66<\/td>\nForward P\/E Ratio Rank<\/strong><\/td>\n73<\/td>\n<\/tr>\n
PEG Ratio<\/strong><\/td>\nn\/a<\/td>\nPEG Ratio Rank<\/strong><\/td>\nn\/a<\/td>\n<\/tr>\n
Price\/Sales<\/strong><\/td>\n2.87<\/td>\nPrice\/Sales Rank<\/strong>(?<\/a>)<\/td>\n37<\/td>\n<\/tr>\n
Market\/Book<\/strong><\/td>\n4.00<\/td>\nMarket\/Book Rank<\/strong>(?<\/a>)<\/td>\n32<\/td>\n<\/tr>\n
Beta<\/strong><\/td>\n1.03<\/td>\nBeta Rank<\/strong><\/td>\n39<\/td>\n<\/tr>\n
Alpha<\/strong><\/td>\n-0.01<\/td>\nAlpha Rank<\/strong><\/td>\n43<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n

ValuEngine.com is an Independent Research Provider (IRP), producing buy\/hold\/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.
\nContact ValuEngine at (800) 381-5576 or support@valuengine.com
\nVisit www.ValuEngine.com for more information<\/strong><\/a><\/p>\n

<\/h1>\n

ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuENgine’s award-winning stock research.
\nContact ValuEngine Capital at info@valuenginecapital.com
\nVisit www.ValuEngineCapital.com for more information<\/strong><\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

This week, we provide top-five ranked VE data for our Medical stocks. We take a look at our latest data on Intel $INTC. We currently have an overvaluation watch underway. VALUATION WATCH: Overvalued stocks now make up 64.57% of our stocks assigned a valuation and 31.59% of those equities are calculated to be overvalued by … Read more<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[39],"tags":[346,343,339,347,349,345,353,352,65,66,338,344,11,348,350,50,44,341,340,62,337,342,9,7,64,351,68,67,63],"_links":{"self":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/679"}],"collection":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/comments?post=679"}],"version-history":[{"count":2,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/679\/revisions"}],"predecessor-version":[{"id":681,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/679\/revisions\/681"}],"wp:attachment":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/media?parent=679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/categories?post=679"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/tags?post=679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}